ValiRx (AIM: VAL), the cancer therapeutics company, today announces that it has signed a new agreement with Physiomics plc (‘Physiomics’) (AIM: PYC), the European systems biology simulation company, to use Physiomics’ In Silico simulations of cellular processes to reduce the development time and costs associated in identifying new therapeutic compounds for the treatment of cancers.
ValiRx’s subsidiary, Cronos Therapeutics Limited – developers of GeneICE – will be the first ValiRx entity to use Physiomics’ technology.
It is anticipated that by coupling GeneICE’s ability to act on genes directly with the predictive capacity of Physiomics’ modeling expertise in biological
systems, it will be possible to optimise the development of possible therapies in terms of time and cost.
Dr Paul Harper, a Director of Physiomics, said:
‘We look forward to deploying our simulation models to help predict and select the optimal targets for ValiRx’s break-through GeneICE technology.’
Dr Satu Vainikka, CEO of ValiRx, added:
‘Correct target selection at the outset is critical to reducing the time spent – and often lost – in the clinical trial process. We view our relationship with
Physiomics as important.’
The primary concentration of the initial programme will be to investigate the process of Apoptosis (the natural process of programmed cell death and
turnover) – a process that is frequently disrupted in Cancers.
ValiRx plc Dr Satu Vainikka +44 (0) 207 408 5400
WH Ireland David Youngman +44 (0) 161 832 2174
Physiomics plc Dr Paul Harper +44 (0) 7747 842446
GTH Communications Toby Hall/ Jade Mamarbachi +44 (0) 20 7153 8035